Researchers have identified a new target for an aggressive type of blood cancer, offering a promising treatment option that could keep patients well for longer, with fewer side effects. 

Scientists at The Institute of Cancer Research, London, and The University of Edinburgh, discovered that blocking the TUT4/7 enzymes can significantly halt growth of acute myeloid leukaemia (AML) cells in the lab and improve survival in mice, without affecting normal production of blood cells. 

Around 150,000 people are diagnosed with AML globally each year, and around 60% of patients die within a year of diagnosis. Current treatments often fail to kill all AML cells, and treatments can have significant side effects such as serious infections, bleeding, and fatigue, as they damage healthy blood cell production. 

The research, published in the journal Science Advances, identified two enzymes that AML cells are heavily dependent on, but that normal blood cells can function without having. 

In research funded by Cancer Research UK and The Institute of Cancer Research (ICR), the team studied the impact of inhibiting the function of the enzymes, TUT4/7. These enzymes modify RNA. While DNA is the genetic store of information for making proteins, RNA is the copy of that information that is used when proteins are being made. 

A new therapeutic approach for AML 

RNA biology is considered the new frontier in medicine, with some RNA-targeting inhibitors currently in clinical trials for the treatment of cancer. 

When the team genetically removed these enzymes in mice, the cancer was slower to develop and grow, and the mice survived for longer. They then treated AML cells with an experimental drug to inhibit TUT4/7 and saw that the cancer cells died. 

One of the current treatments for AML is the drug venetoclax. The team tested this drug in combination with the TUT4/7 inhibitor and found that the combination killed more AML cells than either treatment on its own. 

Importantly, the researchers found that removing TUT4/7 did not harm healthy blood cells. Mice lacking the enzymes remained healthy throughout their lives, with no signs of serious blood problems or other major side effects. 

Professor Kamil Kranc, Professor of Haemato-Oncology at The Institute of Cancer Research, London, who co-led the study, said: “Treatment options for acute myeloid leukaemia have changed little for patients in decades, and there remains an urgent need for more effective and less toxic therapies. Our study has identified two enzymes, TUT4 and TUT7, as promising new drug targets that leukaemia cells depend on to survive. Crucially, our research suggests that healthy blood stem cells can function without them, raising the possibility of a treatment that is both effective and less harmful to patients. 

“Our next challenge is to identify and refine drugs that can safely inhibit these enzymes and take the most promising candidates forward into clinical trials. We hope this discovery marks the beginning of a new therapeutic approach for AML and opens the door to treatments that could work alongside existing therapies to improve patient outcomes.”